JP5576874B2 - モノアシルグリセロールリパーゼの薬物標的化と関連する方法及び組成物 - Google Patents

モノアシルグリセロールリパーゼの薬物標的化と関連する方法及び組成物 Download PDF

Info

Publication number
JP5576874B2
JP5576874B2 JP2011536316A JP2011536316A JP5576874B2 JP 5576874 B2 JP5576874 B2 JP 5576874B2 JP 2011536316 A JP2011536316 A JP 2011536316A JP 2011536316 A JP2011536316 A JP 2011536316A JP 5576874 B2 JP5576874 B2 JP 5576874B2
Authority
JP
Japan
Prior art keywords
magl
cells
cancer
jzl184
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011536316A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508737A5 (https=
JP2012508737A (ja
Inventor
クラバツト，ベンジヤミン・エフ
ロング，ジヨナサン・ゼツト
リー，ウエイウエイ
ノムラ，ダニエル・ケイ
Original Assignee
ザ スクリプス リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティテュート filed Critical ザ スクリプス リサーチ インスティテュート
Publication of JP2012508737A publication Critical patent/JP2012508737A/ja
Publication of JP2012508737A5 publication Critical patent/JP2012508737A5/ja
Application granted granted Critical
Publication of JP5576874B2 publication Critical patent/JP5576874B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2011536316A 2008-11-14 2009-11-10 モノアシルグリセロールリパーゼの薬物標的化と関連する方法及び組成物 Expired - Fee Related JP5576874B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19928608P 2008-11-14 2008-11-14
US61/199,286 2008-11-14
PCT/US2009/006045 WO2010056309A2 (en) 2008-11-14 2009-11-10 Methods and compositions related to targeting monoacylglycerol lipase

Publications (3)

Publication Number Publication Date
JP2012508737A JP2012508737A (ja) 2012-04-12
JP2012508737A5 JP2012508737A5 (https=) 2012-12-13
JP5576874B2 true JP5576874B2 (ja) 2014-08-20

Family

ID=42170582

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011536316A Expired - Fee Related JP5576874B2 (ja) 2008-11-14 2009-11-10 モノアシルグリセロールリパーゼの薬物標的化と関連する方法及び組成物

Country Status (6)

Country Link
US (1) US8772318B2 (https=)
EP (1) EP2373315A4 (https=)
JP (1) JP5576874B2 (https=)
AU (1) AU2009314629B2 (https=)
CA (1) CA2743861A1 (https=)
WO (1) WO2010056309A2 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9487495B2 (en) 2012-01-06 2016-11-08 The Scripts Research Institute Carbamate compounds and of making and using same
EP2828253A1 (en) * 2012-03-19 2015-01-28 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
ES2753386T3 (es) 2013-03-13 2020-04-08 Forma Therapeutics Inc Derivados de 2-hidroxi-1-{4-[(4-fenil)fenil]carbonil}piperazin-1-il}etano-1-ona y compuestos relacionados como inhibidores de sintasa de ácido graso (FASN) para el tratamiento del cáncer
WO2015179563A2 (en) 2014-05-22 2015-11-26 Abide Therapeutics, Inc. N-hydroxy bicyclic hydantoin carbamates as tools for identification of serine hydrolase targets
ES2878041T3 (es) 2015-03-18 2021-11-18 H Lundbeck As Carbamatos de piperazina y métodos para prepararlos y usarlos
SG10202012002TA (en) 2015-05-11 2021-01-28 Lundbeck La Jolla Research Center Inc Methods of treating inflammation or neuropathic pain
UA121775C2 (uk) 2015-07-31 2020-07-27 Пфайзер Інк. 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl
EP3331536A4 (en) * 2015-08-03 2019-03-27 The Regents of The University of California COMPOSITIONS AND METHODS OF MODULATING THE ABHD2 ACTIVITY
US10336709B2 (en) 2015-10-02 2019-07-02 Abide Therapeutics, Inc Lp-PLA2 inhibitors
WO2017143283A1 (en) 2016-02-19 2017-08-24 Abide Therapeutics, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
WO2017222713A1 (en) * 2016-06-24 2017-12-28 Indiana University Research & Technology Corporation A gpr119-based signaling system in the murine eye regulates intraocular pressure in a sex-dependent manner
JP7042804B2 (ja) 2016-09-19 2022-03-28 ルンドベック ラ ホーヤ リサーチ センター，インク． ピペラジンカルバメート、及びその製造と使用の方法
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
EP3571191A1 (en) 2017-01-20 2019-11-27 Pfizer Inc 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
EP3571202B1 (en) 2017-01-23 2021-06-30 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
EP4335848A3 (en) 2017-03-13 2024-06-19 Lundbeck La Jolla Research Center, Inc. Dual magl and faah inhibitors
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
EA201992409A1 (ru) 2017-05-23 2020-03-23 Лундбекк Ла-Хойя Рисерч Сентер, Инк. Ингибиторы magl на основе пиразола
US20210069230A1 (en) * 2018-04-13 2021-03-11 The Broad Institute, Inc. Synergistic drug combinations predicted from genomic features and single-agent response profiles
KR20210010475A (ko) 2018-05-15 2021-01-27 룬드벡 라 졸라 리서치 센터 인코포레이티드 Magl 저해제
AU2019304198A1 (en) 2018-07-19 2021-02-04 Pfizer Inc. Heterocyclic spiro compounds as MAGL inhibitors
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
US11147805B2 (en) * 2019-02-07 2021-10-19 Medipure Pharmaceuticals Inc. Cannabinoid receptor agonists and serine hydrolase enzyme inhibitor based anxiolytic therapeutic product
CN109750104A (zh) * 2019-03-18 2019-05-14 南通大学附属医院 Abhd6在非小细胞肺癌诊断、预后、治疗产品中的应用
WO2021062232A1 (en) * 2019-09-26 2021-04-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for reducing rewarding effects of morphine without affecting its analgesic effects
IL297470A (en) 2020-04-21 2022-12-01 H Lundbeck As Synthesis of a monoacylglycerol lipase inhibitor
TW202304932A (zh) * 2021-04-01 2023-02-01 日商小野藥品工業股份有限公司 Abhd6拮抗劑
CN113527270B (zh) * 2021-07-16 2024-03-01 河南大学 一种靶向单酰基甘油脂肪酶的protac分子的医药中间体、制备方法及应用
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
JP7852604B2 (ja) * 2022-09-30 2026-04-28 小野薬品工業株式会社 Ａｂｈｄ６アンタゴニストを含有する医薬組成物
EP4665718A1 (en) 2023-02-13 2025-12-24 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003262515A1 (en) 2002-09-19 2004-04-08 Nieland, John Mr Inhibitors of the fatty acid oxidation for the prophylaxis and/or the treatment of chronic and/or atopic skin diseases
WO2006058088A2 (en) * 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
WO2006116773A2 (en) * 2005-04-28 2006-11-02 The Regents Of The University Of California Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders
WO2008024408A2 (en) * 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
FR2915197B1 (fr) * 2007-04-18 2009-06-12 Sanofi Aventis Sa Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique.
US7989623B2 (en) * 2007-11-21 2011-08-02 Synthon Bv Process for making n-(diphenylmethyl)piperazines
MX342128B (es) 2008-12-24 2016-09-14 Bial - Portela & C A S A Compuestos farmaceuticos.

Also Published As

Publication number Publication date
US20110275650A1 (en) 2011-11-10
AU2009314629A1 (en) 2010-05-20
EP2373315A2 (en) 2011-10-12
WO2010056309A2 (en) 2010-05-20
WO2010056309A3 (en) 2010-07-01
CA2743861A1 (en) 2010-05-20
US8772318B2 (en) 2014-07-08
AU2009314629B2 (en) 2014-09-25
JP2012508737A (ja) 2012-04-12
EP2373315A4 (en) 2012-06-27

Similar Documents

Publication Publication Date Title
JP5576874B2 (ja) モノアシルグリセロールリパーゼの薬物標的化と関連する方法及び組成物
JP2012508737A5 (https=)
Burnstock et al. The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression
ES2714453T3 (es) Fármacos para inhibir la agregación de proteínas implicadas en enfermedades relacionadas con enfermedades neurodegenerativas y/o agregación de proteínas
JP6952097B2 (ja) ラミノパシー、老化及び癌を治療又は予防するためのｎａｔ１０モジュレーター
US7538252B2 (en) Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
Bisogno et al. A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2‐arachidonoylglycerol with potential anti‐obesity effects
US20210369731A1 (en) Covalent targeting of e3 ligases
US8324279B2 (en) Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase
US9108930B2 (en) N1- and N2-carbamoyl-1,2,3-triazole serine hydrolase inhibitors and methods
Yester et al. Extracellular and intracellular sphingosine-1-phosphate in cancer
CN103239720A (zh) 治疗或缓解疼痛的物质
Zhou et al. Discovery of N-alkyl catecholamides as selective phosphodiesterase-4 inhibitors with anti-neuroinflammation potential exhibiting antidepressant-like effects at non-emetic doses
AU2007267593B2 (en) Macrophage migration inhibitory factor antagonists and methods of using same
CN115701991A (zh) 吡唑基丙酰胺化合物及其用于治疗前列腺癌的用途
Zhao et al. Design, synthesis, and biological evaluation of indoline and Indole derivatives as potent and selective α1A-adrenoceptor antagonists
Wang et al. Eg5 inhibitor YL001 induces mitotic arrest and inhibits tumor proliferation
Yue et al. Development of hydrazide-based hdac6 selective inhibitors for treating nlrp3 inflammasome-related diseases
US9249128B2 (en) Anti-cancer serine hydrolase inhibitory carbamates
Wang et al. Competitive antagonism of KAT7 crotonylation against acetylation affects procentriole formation and colorectal tumorigenesis
Kim et al. Phloroglucinol Derivatives Exert Anti‐Inflammatory Effects and Attenuate Cognitive Impairment in LPS‐Induced Mouse Model
CN106562951B (zh) 一种呋喃类d-3-磷酸甘油酸脱氢酶别构抑制剂及其应用
Chen et al. Natural derivatives of selective HDAC8 inhibitors with potent in Vivo Antitumor efficacy against breast cancer
Xie et al. Orally bioavailable prodrugs of ψ-GSH: a potential treatment for Alzheimer’s disease
CN1237968C (zh) 抑制癌细胞的增殖和诱导其凋亡的方法

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20121026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140509

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140704

R150 Certificate of patent or registration of utility model

Ref document number: 5576874

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees